Lorenzatti A.J.
184
Coauthors
5
Documentos
Volumen de publicaciones por año
Cargando gráfico
| Año de publicación | Num. Publicaciones |
|---|---|
| 2017 | 3 |
| 2021 | 1 |
| 2022 | 1 |
Publicaciones por áreas de conocimiento
Cargando gráfico
| Área de conocimiento | Num. Publicaciones |
|---|---|
| Enfermedad cardiovascular | 5 |
| Medicina interna | 4 |
Publicaciones por áreas temáticas
Cargando gráfico
| Área temática | Num. Publicaciones |
|---|---|
| Enfermedades | 4 |
| Farmacología y terapéutica | 4 |
| Medicina y salud | 3 |
| Problemas sociales y servicios a grupos | 1 |
| Gestión y servicios auxiliares | 1 |
Principales fuentes de datos
| Origen | Num. Publicaciones |
|---|---|
| Scopus | 5 |
| Google Scholar | 3 |
| RRAAE | 0 |
Cargando gráfico
Coautores destacados por número de publicaciones
| Coautor | Num. Publicaciones |
|---|---|
| PATRICIO LOPEZ -JARAMILLO | 4 |
| Ponte-Negretti C.I. | 4 |
| Lozada A.F. | 3 |
| Bryce A. | 3 |
| Piskorz D.L. | 3 |
| Gómez-Mancebo J.R. | 3 |
| Medina J. | 2 |
| Pinto X. | 2 |
| Acevedo M. | 2 |
| Carrera C. | 2 |
Cargando gráfico
Top Keywords
Cargando gráfico
Publicaciones del autor
Considerations and guidance for the structure, organisation, and operation of cardiometabolic prevention units: A consensus statement of the Inter-American Society of Cardiology
ArticleAbstract: Cardiovascular diseases (CVDs) remain the leading cause of death worldwide, particularly in low- andPalabras claves:Cardiometabolic prevention unit, cardiometabolic risk, Cardiovascular preventionAutores:Barbosa E.C.D., Borrayo G., Cobos L., Gómez-Mancebo J.R., López-Santi R., Lorenzatti A.J., Machado L., PATRICIO LOPEZ -JARAMILLO, Piskorz D.L., Ponte-Negretti C.I., Puente-Barragan A., Ruiz E., Sosa-Liprandi Á., Valdéz O., Wyss F.S.Fuentes:googlescopusAtherogenic dyslipidemia in Latin America: Prevalence, causes and treatment. Consensus
ReviewAbstract: Atherogenic dyslipidemia (DA) is a poorly recognized entity in the current clinical practice guideliPalabras claves:Atherogenic dyslipidemia, Highdensity lipoprotein, Low-density lipoprotein, Practical recommendations, TriglyceridesAutores:Acevedo M., Bryce A., Carrera C., Gómez-Mancebo J.R., Isea-Perez J.E., Lanas F.T., Lorenzatti A.J., Lozada A.F., Machado L., Medina J., Morales E., PATRICIO LOPEZ -JARAMILLO, Pinto X., Pirskorz D., Ponte-Negretti C.I., Wyss-Quintana F.S.Fuentes:googlescopusLatin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE)
ArticleAbstract: Background: Hypertension, hyperglycemia, dyslipidemia, overweight, obesity, and tobacco (smoking, chPalabras claves:Atherosclerotic cardiovascular disease, Cardiometabolic risk factors, Cardiovascular Risk, inflammation, Residual risk, ThrombosisAutores:Amaro A.J.J., Badimon J.J., Berrospi P., Bryce A., Cobos S. L., Duran M., Gómez-Mancebo J.R., González J.J.R., Lanas F.T., Lara J., Libby P., Lorenzatti A.J., Lozada A.F., Medina-Palomino F.A., Miranda D., PATRICIO LOPEZ -JARAMILLO, Piskorz D.L., Ponte-Negretti C.I., Puente-Barragan A., Rodrigo A.K., Santos R.D., Toth P.P., Ullauri-Solórzano V.E., Urina-Triana M., Valdés T.O., Villar R., Wyss F.S.Fuentes:scopusAtherogenic Dyslipidemia in Latin America: Prevalence, causes and treatment: Expert's position paper made by The Latin American Academy for the Study of Lipids (ALALIP) Endorsed by the Inter-American Society of Cardiology (IASC), the South American Society of Cardiology (SSC), the Pan-American College of Endothelium (PACE), and the International Atherosclerosis Society (IAS)
ArticleAbstract: This is an executive summary made by a group of experts named Latin American Academy for the study oPalabras claves:Autores:Acevedo M., Alonso R., Arocha I., Bryce A., Carlos Ernesto Peñaherrera, Carrera C., Chirinos J.A., Cobos L., Colan J., Gómez-Alvares E., Gómez-M J.R., Isea-Perez J.E., Lanas F., Lara J., Lorenzatti A.J., Lozada A.F., Machado-H L.T., Medina J., Medina-Palomin F., Merchan-V A., Morales E., Paniagua M., PATRICIO LOPEZ -JARAMILLO, Pinto X., Piskorz D.L., Ponte-Negretti C.I., Ullauri V.E., Varleta P., Villar-M R.A., Wyss-Q F.S.Fuentes:scopusCardiovascular efficacy and safety of bococizumab in high-risk patients
ArticleAbstract: BACKGROUND Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilPalabras claves:Autores:Abbott J.D., Amarenco P., Anderson P., Baultrukonis D., Black H., Blake G., Borer J.S., Brunell R., Buonanno M., Carmena R., Chakrabarti A., Chaudhuri S., Chun H., Civeira F., Colquhoun D., Conde D., Cortada J.B., Curto M., Dan G.A., Dearborn-Tomazos J., Edes I., Epsley C., Evans B., Flather M., Foody J., Frederich R., Frolova M., Furie K.L., Gao R., Gelfand E., Glynn R.J., Goetsch M., Grégoire J., Grobbee D., Hessinger D., Hwang J.J., Jacoby D., Jadbabaie F., Jensen H.K., Johnson M., Jukema J.W., Kahan T., Karpov Y., Kastelein J.J.P., Koenig W., Lee C.W., Leiva Pons J.L., Lorenzatti A.J., Lotan C., Maggioni A.P., Manga P., Masiukiewicz U., McCullough L., McMurray J.J.V., McNamara R., McPherson C., Mellbin L., Miller M., Missault L., Montalescot G., Mosterd A., Mridha K., Murin J., Neaton J., Nicolau J.C., Nissen S.E., Noble S., O’Neill B., Piazza G., Pinto D., Ponikowski P., Powell C., Pride Y., Revkin J., Ridker P.M., Sandra Verónica Falconí Peláez, Sansing L.H., Santos R.D., Savolainen M., Savonitto S., Schiele F.N., Schindler J., Schwartz P.F., Shear C.L., Silverman I.E., Solar M., Soran H., Sritara P., Tarasenko L., Tardif J.C., Tökgozoğlu L., Urina M., Vrablik M., Wang E., Wei C., Welty F., White H.D., Wright R.S., Yunis C., Zannad F.Fuentes:googlescopus